- Home
- GILD vs NVO Comparison
GILD vs NVO Comparison
Compare GILD & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | NVO |
|---|---|---|
| Founded | 1987 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4B | 269.6B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | GILD | NVO |
|---|---|---|
| Price | $145.63 | $38.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 18 | 11 |
| Target Price | ★ $146.50 | $51.00 |
| AVG Volume (30 Days) | 5.7M | ★ 18.6M |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | 2.25% | ★ 3.17% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | ★ 6.78 | N/A |
| Revenue | ★ $24,689,000,000.00 | N/A |
| Revenue This Year | $4.68 | N/A |
| Revenue Next Year | $6.10 | $3.30 |
| P/E Ratio | $21.53 | ★ $13.60 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $95.30 | $35.85 |
| 52 Week High | $157.29 | $82.23 |
Technical Indicators
Market Signals| Indicator | GILD | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 32.56 |
| Support Level | $143.09 | $35.85 |
| Resistance Level | $157.29 | $50.30 |
| Average True Range (ATR) | 3.18 | 0.90 |
| MACD | -1.01 | 0.31 |
| Stochastic Oscillator | 37.10 | 40.55 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.